Part:BBa_K5238005
produce tetrahydrofolate to bind to target lilrb3 for the treatment of Alzheimer's disease
Tetrahydrofolate (THF) plays a crucial role as a coenzyme in one-carbon metabolism, which is essential for the proper functioning of the nervous system. Studies have indicated that THF has potential benefits in treating Alzheimer's disease (AD) and depression. It aids in the synthesis of neurotransmitters and DNA methylation, thereby improving cognitive function and mood regulation. Furthermore, THF can lower homocysteine levels, which helps reduce oxidative stress and neuroinflammation, providing therapeutic benefits for individuals with AD and depression[1][2].
In our research, we have demonstrated through molecular docking simulations and molecular interaction experiments that THF can effectively target the latest LilrB3 receptor, which is closely associated with APOE4 in AD and represents a pivotal target. By competitively inhibiting APOE4-LilrB3 receptor binding, this strategy addresses the root cause of amyloid protein generation and deposition, significantly advancing AD treatment and prevention and opening up new avenues for engineered bacterial therapy in AD.
References: 1. Zhang, S.-M., et al. (2002). Folate, vitamin B6, and vitamin B12 intakes in relation to risk of stroke among men. *Stroke*, 33(1), 196-202. 2. Reynolds, E. (2006). Vitamin B12, folic acid, and the nervous system. *The Lancet Neurology*, 5(11), 949-960.
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal EcoRI site found at 972
Illegal EcoRI site found at 1115 - 12INCOMPATIBLE WITH RFC[12]Illegal EcoRI site found at 972
Illegal EcoRI site found at 1115 - 21INCOMPATIBLE WITH RFC[21]Illegal EcoRI site found at 972
Illegal EcoRI site found at 1115 - 23INCOMPATIBLE WITH RFC[23]Illegal EcoRI site found at 972
Illegal EcoRI site found at 1115 - 25INCOMPATIBLE WITH RFC[25]Illegal EcoRI site found at 972
Illegal EcoRI site found at 1115 - 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 997
| None |